Drugs / AT247
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05184868 | Jan → Sep 2022 | type 1 diabetes mellitus | Arecor Limited | Completed | No outcome recorded |
| Phase 1 | NCT03959514 | Apr → Jul 2019 | type 1 diabetes mellitus | Arecor Limited | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AT247 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05184868 ↗ |
| Modality | Protein / enzyme biologic | “insulin aspart” NCT05184868 ↗ |
| Route | Subcutaneous | “Single subcutaneous injection 0.3 U/Kg” NCT03959514 ↗ |